By Jeff Overley ( March 20, 2015, 6:33 PM EDT) -- Sandoz Inc.'s triumph over Amgen Inc. in the first big court fight over key provisions of the Biologics Price Competition and Innovation Act carries major implications for a coming wave of biosimilars and related litigation, attorneys say. Here are three things to watch in the aftermath....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.